Taura Naota, Hamasaki Keisuke, Nakao Kazuhiko, Ichikawa Tatsuki, Nishimura Daisuke, Goto Takashi, Fukuta Mariko, Kawashimo Hiroshi, Fujimoto Masumi, Kusumoto Koichiro, Motoyoshi Yasuhide, Shibata Hidetaka, Eguchi Katsumi
First Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto, Nagasaki, Japan.
Clin Gastroenterol Hepatol. 2006 Sep;4(9):1177-83. doi: 10.1016/j.cgh.2006.06.008. Epub 2006 Aug 8.
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. However, although the therapeutic approaches for HCC have progressed rapidly, it remains unknown whether the current management of patients with HCC has reduced its mortality. We analyzed changes of survival rate in patients with HCC over a 20-year period.
Between 1982 and 2001, 463 patients were diagnosed with HCC at our hospital. Subjects were enrolled in the current cohort according to the following inclusion criteria: HCC lesion measuring less than 3 cm in diameter, no evidence of extrahepatic metastasis, and no evidence of main portal vein infiltration/thrombosis. A total of 257 patients with HCC were recruited for this study, and categorized into 5-year intervals.
The survival rates improved significantly during the study period. When the patients were stratified according to Child-Pugh score, only patients with Child's B showed improved survival rates. Furthermore, patients with surgical resection or transarterial chemoembolization during the latter period had a better prognosis than those during the early period.
Our findings suggest that the development of therapeutic interventions for HCC have led to improvements in the prognosis for HCC patients.
肝细胞癌(HCC)是全球最常见的癌症之一。然而,尽管HCC的治疗方法发展迅速,但目前HCC患者的管理是否降低了其死亡率仍不清楚。我们分析了20年间HCC患者生存率的变化。
1982年至2001年间,我院有463例患者被诊断为HCC。根据以下纳入标准将受试者纳入当前队列:HCC病变直径小于3 cm,无肝外转移证据,无主门静脉浸润/血栓形成证据。本研究共招募了257例HCC患者,并按5年间隔进行分类。
在研究期间,生存率显著提高。当根据Child-Pugh评分对患者进行分层时,只有Child B级患者的生存率有所提高。此外,后期接受手术切除或经动脉化疗栓塞的患者预后优于早期患者。
我们的研究结果表明,HCC治疗干预措施的发展已使HCC患者的预后得到改善。